Chaperone and anti-chaperone: Two-faced synuclein as stimulator of synaptic evolution

Neuropathology

Volumn 26, Issue 5, 2006, Pages 383-392

  Fujita, Masayo ^a   Wei, Jianshe ^a   Nakai, Masaaki ^a   Masliah, Eliezer ^b   Hashimoto, Makoto ^a  

^a TOKYO METROPOLITAN INSTITUTE OF MEDICAL SCIENCE   (Japan)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Chaperone; Evolvability; Mutation; Parkinson's disease (PD); Synuclein (syn)

Indexed keywords

ALPHA SYNUCLEIN; BETA SYNUCLEIN; CARRIER PROTEIN; CHAPERONE; COTRANSPORTER; CYSTEINE; HEAT SHOCK COGNATE PROTEIN 70; PROTEIN APLP2; PROTEIN DERIVATIVE; PROTEIN KINASE B; PROTEIN MAP2C; UNCLASSIFIED DRUG;

BRAIN DISEASE; CELL SURVIVAL; DIFFUSE LEWY BODY DISEASE; DRUG POTENCY; ENVIRONMENTAL FACTOR; FUNCTIONAL PROTEOMICS; GENE DELETION; MISSENSE MUTATION; MOLECULAR EVOLUTION; NERVE DEGENERATION; NEUROBIOLOGY; NEUROPATHOLOGY; NEUROPHYSIOLOGY; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN SYNTHESIS; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION; SYNAPSE;

ANIMALS; BRAIN; HUMANS; MOLECULAR CHAPERONES; NEURODEGENERATIVE DISEASES; SIGNAL TRANSDUCTION; SYNAPSES; SYNUCLEINS;

EID: 33749031279     PISSN: 09196544     EISSN: 14401789     Source Type: Journal    
DOI: 10.1111/j.1440-1789.2006.00732.x     Document Type: Review

References (63)

1. Hashimoto M, Masliah E. Alpha-synuclein in Lewy body disease and Alzheimer's disease. Brain Pathol 1999; 9: 707-720.
2. Hashimoto M, Hernandez-Ruiz S, Hsu L et al. Human recombinant NACP/α-synuclein is aggregated and fibrillated in vitro: relevance for Lewy body disease. Brain Res 1998; 799: 301-306.
3. Lansbury PT Jr. Evolution of amyloid: what normal protein folding may tell us about fibrillogenesis and disease. Proc Natl Acad Sci USA 1999; 96: 3342-3344.
4. Maroteaux L, Campanelli JT, Scheller RH. Synuclein: a neuron-specific protein localized to the nucleus and presynaptic nerve terminal. J Neurosci 1988; 8: 2804-2815.
5. Ueda K, Fukushima H, Masliah E et al. Molecular cloning of cDNA encoding an unrecognized component of amyloid in Alzheimer disease. Proc Natl Acad Sci USA 1993; 90: 11282-11286.
6. George JM, Jin H, Woods WS, Clayton DF. Characterization of a novel protein regulated during the critical period for song learning in the zebra finch. Neuron 1995; 15: 361-372.
7. Nakajo S, Tsukada K, Omata K, Nakamura Y, Nakaya K. A new brain-specific 14-kDa protein is a phosphoprotein. Its complete amino acid sequence and evidence for phosphorylation. Eur J Biochem 1993; 217: 1057-1063.
8. Ji H, Liu YE, Jia T et al. Identification of a breast cancer-specific gene, BCSG1, by direct differential cDNA sequencing. Cancer Res 1997; 57: 759-764.
9. Jakes R, Spillantini MG, Goedert M. Identification of two distinct synucleins from human brain. FEBS Lett 1994; 345: 27-32.
10. Selkoe DJ. Alzheimer's disease: genes, proteins, and therapy. Physiol Rev 2001; 81: 741-766.
11. Lee VM, Trojanowski JQ. Neurodegenerative tauopathies: human disease and transgenic mouse models. Neuron 1999; 24: 507-510.
12. Goedert M, Crowther RA, Garner CC. Molecular characterization of microtubule-associated proteins tau and MAP2. Trends Neurosci 1991; 14: 193-199.
13. Golaniska E, Flirski M, Liberski PP. Doppel: the prion's double. Folia Neuropathol 2004; 42 (Suppl A): 47-54.
14. Rothstein JD, Dykes-Hoberg M, Corson LB et al. The copper chaperone CCS is abundant in neurons and astrocytes in human and rodent brain. J Neurochem 1999; 72: 422-429.
15. Yamada M, Tsuji S, Takahashi H. Pathology of CAG repeat diseases. Neuropathology 2000; 20: 319-325.
16. Masliah E, Rockenstein E, Veinbergs I et al. Dopaminergic loss and inclusion body formation in alpha-synuclein mice: implications for neurodegenerative disorders. Science 2000; 287: 1265-1269.
17. Hashimoto M, Rockenstein E, Mante M, Mallory M, Masliah E. beta-Synuclein inhibits alpha-synuclein aggregation: a possible role as an anti-parkinsonian factor. Neuron 2001; 32: 213-223.
18. Rockenstein E, Hansen LA, Mallory M, Trojanowski JQ, Galasko D, Masliah E. Altered expression of the synuclein family mRNA in Lewy body and Alzheimer's disease. Brain Res 2001; 914: 48-56.
19. Uversky VN, Li J, Souillac P et al. Biophysical properties of the synucleins and their propensities to fibrillate: inhibition of alpha-synuclein assembly by beta- and gamma-synucleins. J Biol Chem 2002; 277: 11970-11978.
20. Park JY, Lansbury PT Jr. Beta-synuclein inhibits formation of alpha-synuclein protofibrils: a possible therapeutic strategy against Parkinson's disease. Biochemistry 2003; 42: 3696-3700.
21. Lashuel HA, Hartley D, Petre BM, Walz T, Lansbury PT Jr. Neurodegenerative disease: amyloid pores from pathogenic mutations. Nature 2002; 418: 291.
22. Masliah E, Hashimoto M. Development of new treatments for Parkinson's disease in transgenic animal models: a role for beta-synuclein. Neurotoxicology 2002; 23: 461-468.
23. Lee D, Paik SR, Choi KY. Beta-synuclein exhibits chaperone activity more efficiently than alpha-synuclein. FEBS Lett 2004; 576: 256-260.
24. Ostrerova N, Petrucelli L, Farrer M et al. alpha-Synuclein shares physical and functional homology with 14-3-3 proteins. J Neurosci 1999; 19: 5782-5791.
25. Iwata A, Miura S, Kanazawa I, Sawada M, Nukina N. alpha-Synuclein forms a complex with transcription factor Elk-1. J Neurochem 2001; 77: 239-252.
26. Ghee M, Fournier A, Mallet J. Rat alpha-synuclein interacts with Tat binding protein 1, a component of the 26S proteasomal complex. J Neurochem 2000; 75: 2221-2224.
27. Snyder H, Mensah K, Hsu C et al. beta-Synuclein reduces proteasomal inhibition by alpha-synuclein but not gamma-synuclein. J Biol Chem 2005; 280: 7562-7569.
28. Bonifati V. Genetics of Parkinson's disease. Minerva Med 2005; 96: 175-186.
29. Kim RH, Peters M, Jang Y et al. DJ-1, a novel regulator of the tumor suppressor PTEN. Cancer Cell 2005; 7: 263-273.
30. Unoki M, Nakamura Y. Growth-suppressive effects of BPOZ and EGR2, two genes involved in the PTEN signaling pathway. Oncogene 2001; 20: 4457-4465.
31. Hashimoto M, Bar-On P, Ho G et al. Beta-synuclein regulates Akt activity in neuronal cells. A possible mechanism for neuroprotection in Parkinson's disease. J Biol Chem 2004; 279: 23622-23629.
32. Bijur GN, Jope RS. Opposing actions of phosphatidylinositol 3-kinase and glycogen synthase kinase-3beta in the regulation of HSF-1 activity. J Neurochem 2000; 75: 2401-2408.
33. Nakagomi S, Suzuki Y, Namikawa K, Kiryu-Seo S, Kiyama H. Expression of the activating transcription factor 3 prevents c-Jun N-terminal kinase-induced neuronal death by promoting heat shock protein 27 expression and Akt activation. J Neurosci 2003; 23: 5187-5196.
34. Sato S, Fujita N, Tsuruo T. Modulation of Akt kinase activity by binding to Hsp90. Proc Natl Acad Sci USA 2000; 97: 10832-10837.
35. da Costa CA, Masliah E, Checler F. Beta-synuclein displays an antiapoptotic p53-dependent phenotype and protects neurons from 6-hydroxydopamine-induced caspase 3 activation: cross-talk with alpha-synuclein and implication for Parkinson's disease. J Biol Chem 2003; 278: 37330-37335.
36. Culmsee C, Mattson MP. p53 in neuronal apoptosis. Biochem Biophys Res Commun 2005; 331: 761-777.
37. Hashimoto M, Rockenstein E, Mante M et al. An antiaggregation gene therapy strategy for Lewy body disease utilizing beta-synuclein lentivirus in a transgenic model. Gene Ther 2004; 11: 1713-1723.
38. Noguchi CT, Rodgers GP, Schechter AN. Intracellular polymerization. Disease severity and therapeutic predictions. Ann N Y Acad Sci 1989; 565: 75-82.
39. Hasegawa K, Yamaguchi I, Omata S, Gejyo F, Naiki H. Interaction between A beta (1-42) and A beta (1-40) in Alzheimer's beta-amyloid fibril formation in vitro. Biochemistry 1999; 38: 15514-15521.
40. Rochet JC, Conway KA, Lansbury PT Jr. Inhibition of fibrillization and accumulation of prefibrillar oligomers in mixtures of human and mouse alpha-synuclein. Biochemistry 2000; 39: 10619-10626.
41. Hammarstrom P, Schneider F, Kelly JW. Transsuppression of misfolding in an amyloid disease. Science 2001; 293: 2459-2462.
42. Morris CR, Reber AJ, Petersen JL, Vargas SE, Solheim JC. Association of intracellular proteins with folded major histocompatibility complex class I molecules. Immunol Res 2004; 30: 171-179.
43. Sarkar T, Mitra G, Gupta S et al. MAP2 prevents protein aggregation and facilitates reactivation of unfolded enzymes. Eur J Biochem 2004; 271: 1488-1496.
44. Ohtake H, Limprasert P, Fan Y et al. Beta-synuclein gene alterations in dementia with Lewy bodies. Neurology 2004; 63: 805-811.
45. Hemesath TJ, Steingrimsson E, McGill G et al. Microphthalmia, a critical factor in melanocyte development, defines a discrete transcription factor family. Genes Dev 1994; 8: 2770-2780.
46. Wei J, Fujita M, Inoue S, Masliah E, Hashimoto M. Beta-synuclein mutants (V70M,P123H) self-aggregate and stimulate alpha-synuclein aggregation in vitro. Seikagaku 2005; 77: 1043.
47. Yamin G, Munishkina LA, Karymov MA, Lyubchenko YL, Uversky VN, Fink AL. Forcing nonamyloidogenic beta-synuclein to fibrillate. Biochemistry 2005; 44: 9096-9107.
48. Chandra S, Gallardo G, Fernandez-Chacon R, Schluter OM, Sudhof TC. Alpha-synuclein cooperates with CSPalpha in preventing neurodegeneration. Cell 2005; 123: 383-396.
49. Chandra S, Fornai F, Kwon HB et al. Double-knockout mice for alpha- and beta-synucleins: effect on synaptic functions. Proc Natl Acad Sci USA 2004; 101: 14966-14971.
50. Rutherford SL, Lindquist S. Hsp90 as a capacitor for morphological evolution. Nature 1998; 396: 336-342.
51. Queitsch C, Sangster TA, Lindquist S. Hsp90 as a capacitor of phenotypic variation. Nature 2002; 417: 618-624.
52. Rutherford SL. Between genotype and phenotype: protein chaperones and evolvability. Nat Rev Genet 2003; 4: 263-274.
53. Kirschner M, Gerhart J. Evolvability. Proc Natl Acad Sci USA 1998; 95: 8420-8427.
54. Hsu LJ, Mallory M, Xia Y et al. Expression pattern of synucleins (non-Abeta component of Alzheimer's disease amyloid precursor protein/alpha-synuclein) during murine brain development. J Neurochem 1998; 71: 338-344.
55. Lesuisse C, Martin LJ. Long-term culture of mouse cortical neurons as a model for neuronal development, aging, and death. J Neurobiol 2002; 51: 9-23.
56. Shibayama-Imazu T, Ogane K, Hasegawa Y et al. Distribution of PNP 14 (beta-synuclein) in neuroendocrine tissues: localization in Sertoli cells. Mol Reprod Dev 1998; 50: 163-169.
57. Huang P, Miao S, Fan H et al. Expression and characterization of the human YWK-II gene, encoding a sperm membrane protein related to the alzheimer betaA4-amyloid precursorprotein. Mol Hum Reprod 2000; 6: 1069-1078.
58. Behrens A, Genoud N, Naumann H et al. Absence of the prion protein homologue Doppel causes male sterility. Embo J 2002; 21: 3652-3658.
59. Loveland KL, Hayes TM, Meinhardt A et al. Microtubule-associated protein-2 in the rat testis: a novel site of expression. Biol Reprod 1996; 54: 896-904.
60. True HL, Lindquist SL. A yeast prion provides a mechanism for genetic variation and phenotypic diversity. Nature 2000; 407: 477-483.
61. Tanaka M, Chien P, Naber N, Cooke R, Weissman JS. Conformational variations in an infectious protein determine prion strain differences. Nature 2004; 428: 323-328.
62. Tompkins MM, Basgall EJ, Zamrini E, Hill WD. Apoptotic-like changes in Lewy-body-associated disorders and normal aging in substantia nigral neurons. Am J Pathol 1997; 150: 119-131.
63. Tippin B, Pham P, Goodman MF. Error-prone replication for better or worse. Trends Microbiol 2004; 12: 288-295.